News

Article

Nona Biosciences Partners with Boostimmune on ADC Development

Author(s):

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

On Feb. 26, 2024, Nona Biosciences, a wholly owned subsidiary of HBM Holdings Limited, announced that it has entered into a collaboration agreement with Boostimmune, a biotech company specializing in next-generation anti-cancer therapies via modulating immune systems, to develop antibody-drug conjugates (ADCs) against novel targets using Nona’s proprietary Harbour Mice H2L2 (two light and two heavy chain) platform.

The platform technology generates fully human monoclonal antibodies in the classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Nona focuses on integrating its Harbour Mice platform with a single B cell cloning platform to innovate the development of next-generation drugs.

“By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer. Working alongside Boostimmune, we anticipate delivering transformative treatments, ultimately improving outcomes for all patients affected by cancer,” said Jingsong Wang, chairman of Nona Biosciences, in a company press release.

“We are excited to collaborate with Nona Biosciences. Our strategic alignment of resources and knowledge will accelerate the development of ADC therapies against novel targets. Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients,” said Gwanghee Lee, founder and CEO of Boostimmune, in the release.

Source: Nona Biosciences 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content